271 related articles for article (PubMed ID: 20442297)
1. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
[TBL] [Abstract][Full Text] [Related]
3. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
[TBL] [Abstract][Full Text] [Related]
5. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
Laussmann MA; Passante E; Hellwig CT; Tomiczek B; Flanagan L; Prehn JH; Huber HJ; Rehm M
J Biol Chem; 2012 Apr; 287(18):14402-11. PubMed ID: 22408249
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
Koschny R; Boehm C; Sprick MR; Haas TL; Holland H; Xu LX; Krupp W; Mueller WC; Bauer M; Koschny T; Keller M; Sinn P; Meixensberger J; Walczak H; Ganten TM
J Neuropathol Exp Neurol; 2014 Nov; 73(11):1034-46. PubMed ID: 25289891
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP; Premkumar DR; Pollack IF
Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
[TBL] [Abstract][Full Text] [Related]
10. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
12. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
14. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage.
Ramp U; Caliskan E; Mahotka C; Krieg A; Heikaus S; Gabbert HE; Gerharz CD
Br J Cancer; 2003 Jun; 88(11):1800-7. PubMed ID: 12771998
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
Brooks AD; Ramirez T; Toh U; Onksen J; Elliott PJ; Murphy WJ; Sayers TJ
Ann N Y Acad Sci; 2005 Nov; 1059():160-7. PubMed ID: 16382051
[TBL] [Abstract][Full Text] [Related]
18. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
Perez LE; Parquet N; Meads M; Anasetti C; Dalton W
Eur J Haematol; 2010 Mar; 84(3):212-22. PubMed ID: 19922463
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]